Emily Spiegel
About Emily Spiegel
Emily Spiegel is the Associate Director of Business Development, Oncology Search & Evaluation at Bristol Myers Squibb in Cambridge, Massachusetts.
Title
Emily Spiegel is the Associate Director of Business Development, Oncology Search & Evaluation at Bristol Myers Squibb. She operates out of Cambridge, Massachusetts, United States.
Current Role at Bristol Myers Squibb
Emily Spiegel currently serves as the Associate Director of Business Development, Oncology Search & Evaluation at Bristol Myers Squibb. In this role, she focuses on identifying and evaluating potential oncology drug candidates and therapies to advance the company's portfolio.
Previous Positions at Bristol Myers Squibb
Emily Spiegel held the position of Senior Manager, Business Development, Oncology Search & Evaluation at Bristol Myers Squibb for 8 months from 2021 to 2022. She worked in the same Cambridge, Massachusetts location where she gained valuable experience in the oncology search and evaluation processes.
Experience at Accenture
Before joining Bristol Myers Squibb, Emily Spiegel worked at Accenture in various roles. She served as a Life Sciences Strategy Consultant in 2021 for 5 months, and as a Life Sciences Consultant from 2020 to 2021 for 2 months. Prior to that, she was a Life Sciences Strategy & Consulting Senior Analyst from 2019 to 2020 and a Strategy & Consulting Analyst from 2018 to 2019, all based in Boston, Massachusetts. Her experience covers a range of strategic consulting services tailored towards the life sciences sector.
Educational Background
Emily Spiegel graduated magna cum laude with honors in Biology from Bryn Mawr College. During her academic career, she distinguished herself through excellence in her studies and earned recognition for her academic achievements.
Publications and Interests
Emily Spiegel is a regular contributing author on topics related to physiology and psychology. She is interested in enhancing the methodologies used to assess and account for patient needs throughout the drug development lifecycle. Her contributions provide insights into better aligning development strategies with patient-specific requirements.